EGF signalling then induces the enrichment of EGFR protein in HSC-3 sEVs in a way that cannot be countered by anti-EGFR antibody cetuximab [155], a therapeutic agent in clinical use for colorectal tumours and other EGFR-driven clinical entities which binds to the extracellular domain of EGFR and blocks ligand binding and signalling [156]. This evidence concerns the gene EGFR and colorectal neoplasm.